1. Scrip
  2. >>Leadership

Merrimack's Slow Ramp-up For Onivyde Prompts Cutbacks

 
• By Joseph Haas

CEO removed as part of 22% staff cut as Merrimack looks to increase runway while awaiting data to add first-line pancreatic cancer to the Onivyde label.

Merrimack Pharmaceuticals Inc. has talked a good game about waiting out the slow uptake of its pancreatic cancer drug Onivyde since its approval last October, but patience seemed to run out on Oct. 3, as the company announced a restructuring that would terminate CEO Robert Mulroy along with 22% of the employee base and save an estimated $200m over the next two years.

Onivyde, a liposomal injectable formulation of irinotecan (Pfizer Inc.'s Camptosar and generics), obtained FDA approval last Oct. 22 as a treatment in combination with fluorouracil (5-FU) and leucovorin for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Executives On The Move: Innate Pharma And Alloy Therapeutics Get New CEOs

Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 
• By Jessica Merrill

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.

More from Scrip

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.